Similar Search Results

Pharmaceutical Innovation, Mortality Reduction, and Economic Growth

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 1998

We perform an econometric investigation of the contribution of pharmaceutical innovation to mortality reduction and … pharmaceutical innovation, there would have been no increase and perhaps even a small decrease in mean age at death, and that new … drugs have increased life expectancy, and lifetime income, by about 0.75-1.0% per annum. The drug innovation measures are …

Persistent link: https://www.econbiz.de/10005778568

Sources of U.S. Longevity Increase, 1960-1997

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2002

models using annual U.S. time-series data on life expectancy, health expenditure, and medical innovation. Reliable annual … data are available for only one type of innovation - new drugs - but pharmaceutical R&D accounts for a significant fraction … innovation (in the form of new drug approvals) and expenditure on medical care (especially public expenditure) contributed to …

Persistent link: https://www.econbiz.de/10005828594

The Output Contributions of Computer Equipment and Personnel: A Firm- Level Analysis

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 1993

This paper examines the output contributions of capital and labor deployed in information systems (IS) at the firm level during the period 1988-91 throughout the business sector, using two different sources of data on these inputs. Our production function estimates suggest that there are...

Persistent link: https://www.econbiz.de/10005828845

The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2002

We hypothesize that pharmaceutical-embodied technical progress increases per capita output via its effect on labor supply (the employment rate and hours worked per employed person). We examine the effect of changes in both the average quantity and average vintage (FDA approval year) of drugs...

Persistent link: https://www.econbiz.de/10005775072

Technology, Monopoly, and the Decline of the Viatical Settlements Industry

Sood, Neeraj; Alpert, Abby; Bhattacharya, Jay - National Bureau of Economic Research (NBER) - 2005

The viatical settlement industry provides an opportunity for terminally-ill consumers, typically HIV patients, to exploit a previously untapped source of equity in existing life insurance contracts to finance consumption and medical expenses. The 1996 introduction and dissemination of effecive...

Persistent link: https://www.econbiz.de/10005089036

The Other Ex-Ante Moral Hazard in Health

Bhattacharya, Jay; Packalen, Mikko - National Bureau of Economic Research (NBER) - 2008

an induced innovation externality. This alternative mechanism, by contrast, causes people to devote an inefficiently high … level of self-protection. As an empirical example of this externality, we analyze the innovation induced by the obesity … epidemic. Obesity is associated with an increase in the incidence of many diseases. The induced innovation hypothesis is that …

Persistent link: https://www.econbiz.de/10005050326

The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2009

The rate of increase of longevity has varied considerably across U.S. states since 1991. This paper examines the effect of the quality of medical care, behavioral risk factors (obesity, smoking, and AIDS incidence), and other variables (education, income, and health insurance coverage) on life...

Persistent link: https://www.econbiz.de/10005660144

The Effect of New Drugs on Mortality from Rare Diseases and HIV

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2001

I investigate the effect of large increases in the number of drugs available to treat rare diseases and HIV on mortality associated with them. Mortality from both diseases declined dramatically following increases in drug approvals. Before the Orphan Drug Act went into effect (between 1979 and...

Persistent link: https://www.econbiz.de/10005720742

New Ideas in Invention

Packalen, Mikko; Bhattacharya, Jay - National Bureau of Economic Research (NBER) - 2015

A key decision in research is whether to try out new ideas or build on more established ideas. In this paper, we evaluate which type of work is more likely to spur further invention. When recent advances create superior opportunities for invention, their adoption as research inputs in the...

Persistent link: https://www.econbiz.de/10011159886

Cities and Ideas

Packalen, Mikko; Bhattacharya, Jay - National Bureau of Economic Research (NBER) - 2015

Faster technological progress has long been considered a key potential benefit of agglomeration. Physical proximity to others may help inventors adopt new ideas in their work by increasing awareness about which new ideas exist and by enhancing understanding of the properties and usefulness of...

Persistent link: https://www.econbiz.de/10011159889